Hoth Therapeutics Files Presentation Materials for Weight Loss Drug and Pipeline Meetings with US Officials

Hoth Therapeutics, Inc.

Prepared presentation for US government officials on weight loss drug HT-VA and broader therapeutics pipeline
HT-001 for skin toxicity from cancer therapy: Phase 2a data and full PK dataset expected Q1 2026
HT-KIT targeting mastocytosis and KIT-driven cancers: IND submission targeted for Q4 2026
HT-ALZ Alzheimer's program: preclinical data showing improved memory and reduced neuroinflammation
HT-VA obesity program licensed from VA; preclinical studies under CRADA initiated Q3 2025

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.